drontal dog flavour xl, 525/504/175 mg
vetoquinol s.a., magny-vernois, 70200 lure, francuska - febantel; pirantelembonat; prazikvantel - tableta - pasa
lysodren
hra pharma rare diseases - Митотан - neoplazme korijena u adrenalinima - antineoplastična sredstva - simptomatsko liječenje naprednog (nereagirajućeg, metastatskog ili relapsacijskog) adrenalnog kortikalnog karcinoma. učinak lysodren na нефункциональности kore nadbubrežne žlijezde karcinom nije instaliran.
angiotec plus 20 mg/1 tableta+ 12.5 mg/1 tableta tableta
farmavita d.o.o. sarajevo - enalapril, hidrohlorotiazid - tableta - 20 mg/1 tableta+ 12.5 mg/1 tableta - 1 tableta sadrži: 20,0 mg enalaprilmaleata i 12,5 mg hidrohlorotiazida
ampril hd 5 mg/1 tableta+ 25 mg/1 tableta tableta
krka farma d.o.o. sarajevo - hidrohlorotiazid, ramipril - tableta - 5 mg/1 tableta+ 25 mg/1 tableta - 1 tableta sadrži: 5,0 mg ramipril 25,0 mg hidrohlorotiazid
ampril hl 2.5 mg/1 tableta+ 12.5 mg/1 tableta tableta
krka farma d.o.o. sarajevo - hidrohlorotiazid, ramipril - tableta - 2.5 mg/1 tableta+ 12.5 mg/1 tableta - 1 tableta sadrži: 2,5 mg ramipril 12,5 mg hidrohlorotiazid
azaran 1 g/1 viala prašak za rastvor za injekciju/infuziju
hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - ceftriakson - prašak za rastvor za injekciju/infuziju - 1 g/1 viala - 1 bočica sa praškom za rastvor za injekciju/infuziju sadrži: 1 g ceftriakson (u obliku ceftriaksondinatrijum, triseskvihidrata)
ampril hl 2.5 mg/1 tableta+ 12.5 mg/1 tableta tableta
krka farma d.o.o. sarajevo - hidrohlorotiazid, ramipril - tableta - 2.5 mg/1 tableta+ 12.5 mg/1 tableta - 1 tableta sadrži: 2,5 mg ramiprila i 12,5 hidrohlorotiazida
ampril hd 5 mg/1 tableta+ 25 mg/1 tableta tableta
krka farma d.o.o. sarajevo - hidrohlorotiazid, ramipril - tableta - 5 mg/1 tableta+ 25 mg/1 tableta - 1 tableta sadrži: 5 mg ramiprila i 25 mg hidrohlorotiazida
vyepti
h. lundbeck a/s - eptinezumab - migrena poremećaja - analgetici - vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.
cabometyx
ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastična sredstva - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.